Point72 Asset Management’s Black Diamond Therapeutics BDTX Stock Holding History

Point72 Asset Management’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$215K	Sell	100,985 -95,756	-49%	-$228K	﹤0.01%	3494
2025 Q4	$478K	Buy	+196,741	New	+$697K	﹤0.01%	3261
2024 Q4	–	Sell	-697,125	Closed	-$3.03M	–	2088
2024 Q3	$3.03M	Buy	+697,125	New	+$3.79M	0.01%	1038
2023 Q4	–	Sell	-1,115,000	Closed	-$3.2M	–	2175
2023 Q3	$3.2M	Sell	1,115,000 -885,000	-44%	-$3.26M	0.01%	1019
2023 Q2	$10.1M	Buy	+2,000,000	New	+$4.08M	0.03%	581
2021 Q1	–	Sell	-605,000	Closed	-$19.4M	–	964
2020 Q4	$19.4M	Buy	+605,000	New	+$19.9M	0.09%	291

Other funds holding BDTX

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Point72 Asset Management's BDTX Position: Q1 2026 in Review

Point72 Asset Management reduced its Black Diamond Therapeutics (BDTX) stake by 49% in Q1 2026, selling an estimated $228K and leaving 100,985 shares worth $215K. The position accounts for ﹤0.01% of the portfolio, ranked #3494.

Point72 Asset Management first reported a position in BDTX in Q4 2020 and has held it in 6 quarters since. The position peaked at $19.4M in Q4 2020. 104 funds tracked by Wall St. Rank hold BDTX as of Q1 2026.

Point72 Asset Management held 100,985 shares of Black Diamond Therapeutics worth $215K as of Q1 2026.
Point72 Asset Management sold 95,756 Black Diamond Therapeutics shares in Q1 2026, an estimated $228K.
Black Diamond Therapeutics made up ﹤0.01% of Point72 Asset Management's portfolio in Q1 2026, its #3494 holding.
Point72 Asset Management first reported a position in Black Diamond Therapeutics in Q4 2020 and has held it in 6 quarters since.
Point72 Asset Management's Black Diamond Therapeutics position peaked at $19.4M in Q4 2020.
104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.